Keyphrases
Neoadjuvant Chemotherapy
100%
Bladder Cancer
100%
Cancer Patients
100%
Poor Prognosis
100%
Lymph Node Positive
100%
Occult Lymph Node Metastasis
100%
Hazard Ratio
40%
Confidence Interval
40%
Upper Tract Urothelial Carcinoma
30%
Adjuvant Chemotherapy
30%
Pelvic Lymph Node Dissection
30%
Radical Cystectomy
30%
Chemotherapy Patients
30%
Sensitivity Analysis
20%
Previously Treated
20%
Clinical Trials
10%
High Risk
10%
Comorbid
10%
Chemotherapy
10%
Multivariable
10%
Cox Proportional Hazards Model
10%
Cancer Mortality
10%
Worse Outcome
10%
Disease Risk
10%
Pathological Stage
10%
Recurrence-free Survival
10%
Univariate Analysis
10%
Lymph Node Ratio
10%
Recurrent Disease
10%
Novel Agents
10%
Survival Estimation
10%
Preoperative Chemotherapy
10%
Additional Time
10%
Invasive Urothelial Carcinoma
10%
Medicine and Dentistry
Bladder Cancer
100%
Neoadjuvant Chemotherapy
100%
Lymph Node
100%
Lymph Node Metastasis
100%
Hazard Ratio
36%
Retroperitoneal Lymph Node Dissection
27%
Transitional Cell Carcinoma
27%
Adjuvant Chemotherapy
27%
Bladder
27%
Cystectomy
27%
Pelvis
27%
Recurrent Disease
9%
Malignant Neoplasm
9%
Clinical Trial
9%
Proportional Hazards Model
9%
Recurrence Free Survival
9%
Univariate Analysis
9%
Survival Estimate
9%
Specific Mortality
9%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Bladder Cancer
100%
Lymph Node Metastasis
100%
Transitional Cell Carcinoma
23%
Malignant Neoplasm
7%
Clinical Trial
7%
Recurrent Disease
7%
Recurrence Free Survival
7%
Immunology and Microbiology
Lymph Node
100%
Pelvis
20%
Recurrence Free Survival
6%
Muscle
6%